CClinicalTrials.gg
RecruitingNCT05643209UNCOVERBrSUpdated Aug 15, 2025

Brugada Syndrome Substrate Characterization and Ablation

An interventional study of ablation in Brugada Syndrome, sponsored by Maria Cecilia Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Maria Cecilia Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Independent, single center, prospective study, to evaluate the efficacy, in consecutive BrS patients undergoing catheter ablation, at medium-long term follow-up after epicardial substrate homogenization. The target area is defined collecting signals using high density and high resolution mapping with equi-spaced electrode array. The ablation of abnormal fragmented prolonged low-frequency ventricular electrograms is performed by contact force catheter.

Read the detailed description

Most of the patients with a diagnosis of Brugada syndrome (BrS) have no history of syncope or resuscitated cardiac arrest at the time of the diagnosis. Risk stratification in these patients is of utmost importance because cardiac arrest may be the presenting symptom. Individuals with a spontaneous electrocardiogram (ECG) BrS type I pattern (J-point and coved ST-segment elevation in the right precordial leads) are at higher risk of life-threating arrhythmic events than those with ECG abnormalities induced by sodium channel blocking agents. However, in the latter category, there may be subgroups of patients more exposed to the risk of arrhythmias. To date, a clear answer to this question has not yet emerged. Although controversial, programmed ventricular stimulation (PVS) is still central in the complex decision-making algorithm used to manage these lower risk BrS patients. A recent pooled analysis has confirmed the predictive role of PVS inidentifying BrS patients at increased risk of cardiac arrest6. Recently, Iacopino et al. demonstrate that the novel dST-Tiso interval >300 msec is a powerful predictor of ventricular arrhythmias inducibility (sensitivity 92% specificity 90%) in subjects with drug-induced BrS type I ECG pattern7. Radiofrequency ablation (RFA) of arrhythmogenic zones in the right ventricular epicardium has emerged over the past decade as a possible future curative treatment option for BrS. However, only a small number of studies with limited follow-up periods have reported successful results with RFA in symptomatic Brugada patients. The first to describe a successful RFA procedure in Brugada were Nademanee et al. using a selected cohort of nine high-risk patients with frequent ICD shocks for ventricular arrhythmias. More recently, Brugada et al.and Nademanee et al. described an improved technique for successful elimination of the Brugada syndrome phenotype with epicardial RFA. The mapping was performed before and after administration of flecainide/ajmaline which resulted in identification of more extensive arrhythmogenic segments in the RV epicardium beyond the RVOT.

Most recently, Iacopino et al. proposed a successful epicardial ablation of the arrhythmogenic substrate in BrS by using a novel and feasible technique with hybrid mini-thoracotomic approach and a 0-fluoroscopy strategy. The novel workflow combines both electrophysiological and surgical skills in a hybrid fashion with the aim to overcome their respective limitations.

Bipolar electrogram (BiEGM)-based substrate maps are heavily influenced by direction of a wavefront to the mapping bipole. Recently, Porta-Sanchez et al. evaluate high-resolution, orientation-independent peak-to-peak voltage (Vpp) maps obtained with an equi-spaced electrode array and omnipolar EGMs (OTEGMs), measure its beat-to-beat consistency, and assess its ability to delineate diseased areas within the myocardium compared against traditional BiEGMs on two orientations: along (AL) and across (AC) array splines and demonstrate that an equi-spaced electrode grid when combined with omnipolar methodology yielded the largest detectable bipolar-like voltage and is void of directional influences, providing reliable voltage assessment within infarcted and non-infarcted regions of the heart.

To date, there is no study that characterized the arrhythmogenic substrate of Brugada patients with the equi-spaced electrode array and omnipolar EGMs (OTEGMs) that are available nowadays.

The published studies regarding epicardial substrate ablation in Brugada patients describe an electrophysiological substrate characterized by abnormal fragmented prolonged low-frequency ventricular electrograms. We believe that the low resolution and the greater electrode dimensions of the conventional catheter can impact on both the duration and morphology of these signals.

The purpose of this study is to investigate the acute and long term efficacy of the protocol proposed which consists in ablating the abnormal fragmented prolonged low-frequency ventricular electrograms detected by equi-spaced electrode array and omnipolar EGMs (OTEGMs). Collecting and analyzing data concerning: late potential and voltage maps using different settings, vector data and speed maps, could be useful to better understand and describe the mechanism of this pathology.

In our expectation, a better definition of the abnormal substrate area dimension, could also confirm a relationship with the novel dST-Tiso interval.

02

Conditions studied

  • Brugada Syndrome

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Symptomatic patients diagnosed with BrS-ECG pattern of types 1 and 2, both spontaneous and arising after Ajmaline tests, already implanted with an ICD.

    Symptomatic patients are defined as those who present ≥1 documented episode of VT / VF in the 12 months prior to enrollment.

  2. Patients eligible for ablation with 3D high-density mapping system in accordance with national guidelines, IFU and according to medical decision;
  3. Adult patients able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Patients unable to provide written informed consent;
  2. Patients unable to guarantee their presence at future FU visits;
  3. Patients who, according to medical judgment, have a life expectancy of less than 12 months;
  4. Patients who have undergone cardiac ablation in the 90 days prior to enrollment.
  5. Patients who have had adverse events that have not been resolved after any invasive procedure;
  6. Women potentially pregnant or planning to become pregnant.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    consecutive patients

    20 patients clinically indicated for a endo-epicardial catheter-based mapping procedure for the treatment of ventricular tachycardia/ ventricular fibrillation substrate

    Procedure: ablation

Interventions

  • Procedureablation

    epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation

05

What researchers measure

Primary outcomes

  1. Percentage of patients free from any clinical ventricular arrhythmia at a 3, 6-months and 12-months follow-up from the procedure.

    The primary aim of the study is the rate of success at medium-long term follow-up after epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive brugada patients undergoing catheter ablation. The medium-long term success of the ablation is defined in terms of percentage of patients free from any clinical ventricular arrhythmia at a 3, 6-months and 12-months follow-up from the procedure.

    Time frame: 12-months

Secondary outcomes

  1. Collecting and analyzing data concerning late potential and voltage maps using different settings, vector data and speed maps, could be useful to better understand and describe the mechanism of this pathology.

    • Comparison among different setting of voltage map (OT vs Standard acquisition)

    Time frame: 12 months

06

Study locations

1 of 1 sites recruiting
  • Maria Cecilia Hospital
    Cotignola, Ravenna 48033, Italy
    • Saverio Iacopino, MD · Contact
    Recruiting
07

References and documents

Publications

  • Iacopino S, Sorrenti PF, Petretta A, Colella J, Di Vilio A, Statuto G, Fabiano G, Campagna G, Peluso G, Fabiano E, Indellicati G, Brogneri S, Tremoli E, Mantovani L, Speziale G, Savini C, Tripodi A. Hybrid mini-thoracotomy for Brugada syndrome: epicardial substrate characterization and ablation-results from UNCOVER(BrS) study. Front Cardiovasc Med. 2025 Oct 28;12:1658355. doi: 10.3389/fcvm.2025.1658355. eCollection 2025. PubMed 41229453 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT05643209
Lead sponsor
Maria Cecilia Hospital
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Feb 1, 2023
Primary completion
May 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Aug 15, 2025

Study contacts

Saverio Iacopino, MD
Contact
siacopino@gvmnet.it
0545.217228
Saverio Iacopino, MD
principal investigator · Maria Cecilia Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion